Natera executive chairman Rabinowitz sells $3.4m in stock

Natera, Inc. (NASDAQ:NTRA) Executive Chairman Matthew Rabinowitz sold 17,100 shares of common stock on November 3, 2025, for a total of $3,420,003. The sales were executed at prices ranging from $200.00 to $200.01 per share, nearly matching the company’s 52-week high of $200.76. With a market capitalization of $27.2 billion, Natera’s stock has delivered an impressive 60.59% return over the past year.

Following the transaction, Rabinowitz directly owns 2,303,752 shares of Natera, Inc. common stock. Additionally, he indirectly owns 5,000 shares through his spouse. InvestingPro data shows Natera trading at a high Price/Book multiple of 21.83, with the company’s earnings report due in just 2 days on November 6.

The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by Rabinowitz on June 13, 2025. While Natera maintains strong liquidity with a current ratio of 3.72, InvestingPro analysis indicates the company is not yet profitable, with a diluted EPS of -$1.92. Discover 14 more key insights and a comprehensive Pro Research Report on Natera through InvestingPro’s detailed analysis.

In other recent news, Natera has reported significant advancements in its early cancer detection program, specifically in identifying advanced adenomas, precancerous polyps that can lead to colorectal cancer. The company’s PROCEED-CRC clinical trial revealed that their blood-based screening test achieved 22.5% sensitivity and 91.5% specificity for detecting these polyps. Meanwhile, Natera’s minimal residual disease (MRD) business has been performing well, as highlighted by Canaccord Genuity, which maintained its Buy rating and $200 price target for the company. This comes after results from the phase 3 IMvigor011 trial showed that Natera’s Signatera test effectively guides adjuvant therapy in muscle-invasive bladder cancer (MIBC) patients.

BTIG also raised its price target for Natera to $210 from $200, maintaining a Buy rating following positive trial results in MIBC. Piper Sandler reiterated its Overweight rating with a $220 price target, emphasizing Natera’s first-mover advantage in the molecular diagnostics space. The research firm noted the company’s strong clinical data and established infrastructure as significant competitive barriers. These developments reflect Natera’s ongoing efforts to solidify its leadership in the field of molecular diagnostics.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.